Evaluation of 111In-labeled cyclic RGD peptides: Tetrameric not tetravalent

Bioconjugate Chemistry

Volumn 21, Issue 5, 2010, Pages 969-978

  Chakraborty, Sudipta ^a   Shi, Jiyun ^a,b   Kim, Young Seung ^a   Zhou, Yang ^a   Jia, Bing ^b   Wang, Fan ^b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES;

ATHYMIC; GLIOMA CELLS; INTEGRINS; NUDE MICE; RADIOLABELLING; REACTION MIXTURE; RGD PEPTIDE; SPECIFIC ACTIVITY; TETRAMERIC; TUMOR UPTAKE;

TUMORS;

(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3GLYCINE ARGINYLGLYCYLASPARTIC ACID 2) INDIUM 111; (1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 6GLYCINE ARGINYLGLYCYLASPARTIC ACID 4)INDIUM 111; (1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ARGINYLGLYCYLASPARTIC ACID 4) INDIUM 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; INDIUM 111; LUTETIUM 177; TETRAMER; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; YTTRIUM 90; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; CYCLOPEPTIDE; DIAGNOSTIC AGENT; GLYCYL GLYCYL GLYCINE; GLYCYL-GLYCYL-GLYCINE; INDIUM; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; CELL STRAIN U87MG; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLIOMA CELL; HEATING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PARTITION COEFFICIENT; PROTEIN BINDING; PROTEIN MOTIF; URINARY EXCRETION; XENOGRAFT; ANIMAL; CHEMISTRY; GLIOMA; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; OLIGOPEPTIDES; PEPTIDES, CYCLIC;

EID: 77952578237     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc900555q     Document Type: Article

References (40)

1. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., and Schwaiger, M. (2001) Tumor angiogenesis targeting using imaging agents Q. J. Nucl. Med. 45, 179-182
2. Costouros, N. G., Diehn, F. E., and Libutti, S. K. (2002) Molecular imaging of tumor angiogenesis J. Cell. Biochem. Suppl. 39, 72-78
3. 3 directed radiopharmaceuticals for tumor imaging Drugs Future 28, 551-564
4. Haubner, R. and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of antiantiogenic therapies Curr. Pharm. Des. 10, 1439-1455
5. 3-targeted radiotracers for tumor imaging Mol. Pharm. 3, 472-487
6. 3 expression Mini-Rev. Med. Chem. 6, 227-234
7. Cai, W. and Chen, X. (2008) Multimodality molecular imaging of tumor angiogenesis J. Nucl. Med. 49, 113S-128S
8. Cai, W., Niu, G., and Chen, X. (2008) Imaging of integrins as biomarkers for tumor angiogenesis Curr. Pharmaceut. Des. 14, 2943-2973
9. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem. [Online early access].
10. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chem. - Eur. J. 9, 2717-2725
11. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation Radiochim. Acta 92, 317-327
12. 64Cu-labeled dimeric RGD peptides Mol. Imaging Biol. 6, 350-359
13. 18F-labeled dimeric RGD peptide Mol. Imaging 3, 96-104
14. 64Cu-labeled tetrameric RGD peptide J. Nucl. Med. 46, 1707-1718
15. 18F-FRGD2 J. Nucl. Med. 47, 113-121 (Pubitemid 46768520)
16. 18F-FPRGD4) J. Nucl. Med. 48, 1536-1544
17. 3 expression Eur. J. Nucl. Med. Mol. Imaging 35, 1100-1108
18. 99mTc-Labeling of a hydrazinonicotinamide- conjugated vitronectin receptor antagonist useful for imaging tumor Bioconjugate Chem. 12, 624-629 (Pubitemid 32696237)
19. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist for tumor therapy Bioconjugate Chem. 12, 559-568
20. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Radjopadhye, M., Corstens, F. H., and Boerman, O. C. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting Cancer Biother. Radiopharm. 17, 641-646
21. 3 binding peptides in a nude mice model Cancer Res. 62, 6146-6151
22. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer Bioconjugate Chem. 16, 1580-1588
23. 3 expression Bioconjugate Chem. 17, 1069-1076
24. 99mTc- labeled cyclic RGDfK dimer Bioconjugate Chem. 17, 1499-1507
25. 3-positive breast cancer Bioconjugate Chem. 18, 438-446
26. 3 integrin by multimerization of RGD peptides Eur. J. Nucl. Med. Mol. Imaging 34, 267-273
27. 111In- labeled RGD Peptide Nucl. Med. Biol. 34, 29-35
28. 111In-labeled DTPA conjugates of a cyclic RGDfK dimer Bioconjugate Chem. 19, 201-210
29. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand Bioconjugate Chem. 19, 634-642
30. 99mTc-labeled cyclic RGDfK tetramer Nucl. Med. Biol. 35, 111-121
31. 99mTc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with triglycine linkers J. Med. Chem. 51, 7980-7990
32. 4 linkers Mol. Pharm. 6, 231-245
33. 4 Linkers Bioconjugate Chem. 20, 750-759
34. 3 PET imaging Eur. J. Nucl. Med. Mol. Imaging 36, 947-957
35. 4 linkers Eur. J. Nucl. Med. Mol. Imaging 36, 1296-1307
36. 99mTc-labeling of cyclic RGD dimers: effects of technetium chelate on tumor uptake and pharmacokinetics Bioconjugate Chem. 20, 1559-1568
37. 3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics Eur. J. Nucl. Med. Mol. Imaging 36, 1874-1884
38. Jain, R. K. (1987) Transport of molecules in the tumor interstitium: a review Cancer Res. 47, 3039-3051
39. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development Mol. Cancer Ther. 5, 2624-2633
40. Niu, G. and Chen, X. (2008) Has molecular and cellular imaging enhanced drug discovery and drug development Drugs R&D 9, 351-368